Phase 3Completed
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
- Sponsor
- Tanabe Pharma Corporation (Industry)
- Enrollment
- 308 enrolled
- Conditions
- Diabetic Nephropathy
- Interventions
- Canagliflozin; Placebo
- Ages
- adults, older adults
- Registry
- NCT03436693
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
Primary outcomes
- Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104
History
Last registry update
Results first posted
Primary completion
Registered
Started
Papers citing this trial
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
The Cochrane database of systematic reviews